The present study, together with our previous findings in prostate cancer (Di Donato et al., 2018, 2019), further points to the relevance of NGF signaling in “gender-related cancers” and paves the way for new therapeutic opportunities in the clinical management of TNBC patients, who often exhibit or develop drug resistance. This evidence concerns the gene NGF and Familial prostate cancer.